Following recognition that nitric oxide (or a closely related compound) possesses vasodilator properties, a number of investigators have recently described a selective pulmonary vasodilator effect of inhaled nitric oxide." In this case report we describe a beneficial haemodynamic effect of inhaled nitric oxide in a patient with severe heart failure complicated by refractory pulmonary hypertension, systemic hypotension and requiring mechanical cardiac support as a bridge to cardiac transplantation.
CASE REPORT
A forty-three-year-old man suffering from an alcohol related dilated cardiomyopathy (LVEF 19070) was admitted with a three-day history of increasing shortness of breath, weight gain (4 kg) and peripheral oedema. On examination the patient was dyspnoeic, with crepitations to chest midzone, consistent with pulmonary oedema. He was hypotensive (blood pressure of 80/50), and tachycardic (100 per minute), the jugular venous pulse was elevated to 10 cm, and there were 2 cm of pulsatile hepatomegaly. He was treated initially with intravenous frusemide (40-250 mg increments IV) and dopamine (3mcg/kg/min), the latter being changed to adrenaline some hours after admission. The next day he developed frank pulmonary oedema requiring endotracheal intubation, intermittent positive pressure ventilation with PEEP and intraaortic balloon counterpulsation. Despite these measures he continued to deteriorate and eventually required implantation of a left ventricular assist device Soon after admission to the Intensive Care Unit, it became apparent that the patient required intravenous fluid loading to a central venous pressure of 20-25 mmHg to secure the delivery of sufficient blood from the right ventricle to the LVAD. It was postulated that reduction of pulmonary vascular resistance (and thus right ventricular afterload) would further enhance right ventricular output. It was believed that use of conventional nonselective vasodilators such as sodium nitroprusside, glyceryl trinitrate or prostacyclin to achieve this would aggravate systemic hypotension and these drugs were therefore contraindicated.
A trial of nitric oxide inhalation at an inspired concentration of 40 parts per miliion (ppm) was therefore conducted to selectively dilate the pulmonary circulation. This was implemented under Category A of the Special Access Scheme (SAS), as defined by Therapeutic Goods Adminstration, Department of Community Services and Health. The method used was to add an accurately metered flow of nitric oxide in nitrogen mixture to the inspiratory limb of the Bennett 7200 ventilator circuit at a flow calculated to achieve 40 ppm of NO in the preset mean flow of inspiratory gas delivered by the ventilator. This method had been validated using a Signal Chemiluminescent NO analyser (courtesy of CIG Hytec, Sydney). To establish the efficacy and reproducibility of NO inhalation, delivery of the gas was ceased for two periods of approximately 45 minutes and appropriate haemodynamic measurements made after circulatory parameters had stabilised. The results, as summarised in Table 1 , indicate a potent and selective dilator effect of nitric oxide on the pulmonary circulation. This ensured a consistent increase in right ventricular output despite lowering the right atrial filling pressure by approximately thirty percent.
Over the next 36 hours, the patient's condition steadily deteriorated to the point where he became anuric, his legs pulseless and white, his abdomen distended and silent. He developed a profound lactic acidosis (serum lactate 36 mmolll) despite full left ventricular support at cardiac outputs over 6l1min and massive inotropic therapy. These findings, consistent with occult tissue death, indicated that mechanical assist had been implemented too late to prevent irreversible shock. At this point all support was electively withdrawn and the patient died soon after.
DISCUSSION
The effectiveness of nitric oxide gas administered by inhalation in concentrations ranging from 5-80 ppm was reported by Frostel et al. 2 and Fractacci et al. ) in animals in 1991. These were quickly followed by reports documenting the efficacy of nitric oxide in the 10-40 ppm range as a selective pulmonary vasodilator in adults' and neonates 5 with pulmonary hypertension. More recently, nitric oxide inhalation has been found to reduce pulmonary artery pressure and hypoxaemia in ARDS.6 This case report illustrates the effectiveness of inhaled nitric oxide as an adjunct to LVAD support in biventricular heart failure. The rationale for use is that, by selectively lowering pulmonary vascular resistance, and thus right ventricular output impedance, it should reduce the right atrial filling pressure required to enhance the output of the failing right ventricle. A lower venous pressure in turn should ameliorate the tendency to hepatic and renal congestion and peripheral oedema. This, together with optimal inotrope dosage, might allow deployment of the simpler and smaller left ventricular assist device in preference to a biventricular assist mechanism.
On the negative side, nitric oxide has the potential to damage tissues either directly or through oxidation to its toxic byproduct, nitrogen dioxide. 7 As the rate of conversion of nitric oxide to nitrogen dioxide is proportional to oxygen concentration and the square of nitric oxide concentration,8 it is important to minimise both the concentration and transit time of nitric oxide in the respiratory circuit. In our study 40 ppm nitric oxide was used on the basis of the experience of Pepke-Zaba et aI.' However, future toxicological studies might well indicate that this level, while effective, is too toxic for long-term administration.
CONCLUSION
In this case report we have described a favourable haemodynamic response to inhaled nitric oxide in a critically ill patient requiring mechanical circulatory support. Our findings suggest that the selective pulmonary vasodilatation provided by nitric oxide inhalation increases the effectiveness of the LVAD in the management of biventricular heart failure. The toxicity of the gas and its by-products, however, renders optimal dosage and the permissible duration of therapy uncertain at this stage.
